Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06503601
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
None
First Post:
2024-07-10
Brief Title:
The Impact of Genetic Polymorphism on the Echocardiographic Parameters and Cardiac Fibrosis Markers in Response to Empagliflozin Treatment Among Patients With Heart Failure
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Impact of Genetic Polymorphism on the Echocardiographic Parameters and Cardiac Fibrosis Markers in Response to Empagliflozin Treatment Among Patients With Heart Failure
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
It is important to assess the implications of genetic variants of the TGF-β1 gene in patients with HFrEF and the association of this polymorphism with treatment response to SGLT2I Therefore by correlating the pharmacogenetics hand in hand with the mechanistic markers involved in the pathogenesis of HF this can aid in the development of individualized therapeutic strategies and improve the patients drug response
Detailed Description:
Cardiovascular diseases are the leading cause of morbidity and mortality worldwide According to the American heart association AHA over 191 million deaths worldwide in 2020 were attributed to CVD Heart failure HF is considered one of the most frequent causes of hospitalization and the final stage of many heart disorders It is associated with high rates of morbidity and mortality Heart failure HF affects more than 58 million people in the USA and over 23 million people worldwide making it a serious public health issue According to the 2022 guidelines of American heart association AHA a variety of non-pharmacologic and pharmacologic are available to treat heart failure HF to prevent or reverse its symptoms Nonpharmacologic treatments may involve dietary sodium and fluid restriction proper physical activity and attention to weight gain depending on the illness39s severity Pharmacologic treatments include the use of diuretics vasodilators inotropic agents anticoagulants beta blockers angiotensin-converting enzyme inhibitors ACEIs angiotensin receptor blockers ARBs calcium channel blockers CCBs digoxin nitrates B-type natriuretic peptides BNPs If inhibitors angiotensin receptor-neprilysin inhibitors ARNIs soluble guanylate cyclase stimulators sodium-glucose cotransporter-2 inhibitors SGLT2Is and mineralocorticoid receptor antagonists MRAs Recent study has shown that SGLT2I not only lowers blood sugar levels but also protects the kidney and heart which can dramatically lower cardiovascular events stall the advancement of renal failure significantly raise patient quality of life and lower medical costs for families and society A study showed that Empagliflozin has cardio-renal protective effects as it reduced inflammatory and fibrotic markers such as NF-κB TGF-β1 and improved fibrosis However it was found that the variation in treatment response with SGLT2I may be due to the genetic polymorphism of TGF-β1 since this polymorphism may influence its expression Therefore it is important to assess the implications of genetic variants of the TGF-β1 gene in patients with HFrEF and the association of this polymorphism with treatment response to SGLT2I Therefore by correlating the pharmacogenetics hand in hand with the mechanistic markers involved in the pathogenesis of HF this can aid in the development of individualized therapeutic strategies and improve the patients drug response
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None